News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
333,980 Results
Type
Article (16597)
Company Profile (229)
Press Release (317149)
Multimedia
Podcasts (110)
Webinars (12)
Section
Business (105257)
Career Advice (176)
Deals (16400)
Drug Delivery (49)
Drug Development (54152)
Employer Resources (31)
FDA (7091)
Job Trends (5606)
News (166249)
Policy (12370)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (2)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (1006)
Accelerated approval (35)
ADA (34)
Adcomms (16)
Allergies (133)
Alliances (26202)
ALS (182)
Alzheimer's disease (1288)
Antibody-drug conjugate (ADC) (493)
Approvals (7494)
Artificial intelligence (427)
ASCO (230)
Autoimmune disease (317)
Automation (17)
Bankruptcy (114)
Best Places to Work (4794)
BIO (55)
BIOSECURE Act (6)
Biosimilars (164)
BioSpace Insights (72)
Biotechnology (179)
Bladder cancer (132)
Brain cancer (63)
Breast cancer (497)
Cancer (4560)
Cardiovascular disease (327)
Career advice (169)
Career pathing (13)
CAR-T (307)
CDC (9)
Celiac Disease (1)
Cell therapy (805)
Cervical cancer (27)
Clinical research (48568)
Collaboration (1691)
Commercialization (5)
Company closure (3)
Compensation (875)
Complete response letters (69)
COVID-19 (1228)
CRISPR (116)
C-suite (908)
Cystic fibrosis (125)
Data (6602)
Denatured (23)
Depression (136)
Dermatology (76)
Diabetes (377)
Diagnostics (1989)
Digital health (21)
Diversity (6)
Diversity, equity & inclusion (9)
Drug discovery (324)
Drug pricing (54)
Drug shortages (3)
Duchenne muscular dystrophy (317)
Earnings (37949)
Editorial (36)
Employer branding (4)
Employer resources (29)
Events (58160)
Executive appointments (778)
FDA (9747)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (24)
Frontotemporal dementia (32)
Funding (1375)
Gene editing (241)
Generative AI (42)
Gene therapy (661)
GLP-1 (636)
Government (1318)
Grass and pollen (4)
Guidances (201)
Healthcare (7293)
Hematology (124)
HIV (37)
Huntington's disease (61)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (112)
Immunology and inflammation (263)
Immuno-oncology (89)
Indications (167)
Infectious disease (1405)
Inflammatory bowel disease (194)
Inflation Reduction Act (10)
Influenza (74)
Intellectual property (242)
Interviews (20)
IPO (8243)
IRA (13)
Job creations (1048)
Job search strategy (143)
JPM (43)
Kidney cancer (12)
Labor market (36)
Layoffs (270)
Leadership (15)
Legal (2155)
Licensing (9)
Liver cancer (58)
Longevity (27)
Lung cancer (620)
Lymphoma (349)
Machine learning (35)
Management (7)
Manufacturing (650)
Marketing (10)
MASH (175)
Medical affairs (1)
Medical device (3697)
Medtech (3751)
Mergers & acquisitions (9060)
Metabolic disorders (1033)
mRNA (182)
Multiple sclerosis (146)
NASH (14)
Neurodegenerative disease (386)
Neuropsychiatric disorders (95)
Neuroscience (2654)
Neurotech (1)
NextGen: Class of 2026 (2160)
Non-profit (927)
Now hiring (42)
Obesity (450)
Opinion (147)
Ovarian cancer (206)
Pain (153)
Pancreatic cancer (270)
Parkinson's disease (346)
Partnered (17)
Patents (456)
Patient recruitment (647)
Peanut (51)
People (30150)
Pharmaceutical (29)
Pharmacy benefit managers (11)
Phase 1 (16823)
Phase 2 (22385)
Phase 3 (14600)
Pipeline (7603)
Policy (108)
Postmarket research (992)
Preclinical (7058)
Press Release (32)
Prostate cancer (224)
Psychedelics (74)
Radiopharmaceuticals (311)
Rare diseases (1013)
Real estate (1914)
Recruiting (12)
Regulatory (12638)
Reports (28)
Research institute (1043)
Resumes & cover letters (20)
Rett syndrome (42)
RNA editing (31)
RSV (25)
Schizophrenia (164)
Series A (265)
Series B (193)
Service/supplier (1)
Sickle cell disease (99)
Special edition (21)
Spinal muscular atrophy (128)
Sponsored (18)
Startups (2242)
State (1)
Stomach cancer (7)
Supply chain (46)
Tariffs (19)
The Weekly (85)
Vaccines (453)
Venture capital (102)
Weight loss (245)
Women's health (53)
Worklife (2)
Date
Today (53)
Last 7 days (346)
Last 30 days (1546)
Last 365 days (19179)
2026 (12226)
2025 (19154)
2024 (21768)
2023 (23963)
2022 (30231)
2021 (31133)
2020 (26588)
2019 (18334)
2018 (13438)
2017 (15632)
2016 (13738)
2015 (16811)
2014 (12452)
2013 (9311)
2012 (9526)
2011 (9706)
2010 (9314)
Location
Africa (210)
Alabama (79)
Alaska (2)
Arizona (102)
Arkansas (7)
Asia (32126)
Australia (4722)
California (9463)
Canada (2526)
China (1329)
Colorado (332)
Connecticut (350)
Delaware (321)
Europe (48542)
Florida (1254)
Georgia (274)
Hawaii (3)
Idaho (18)
Illinois (583)
India (81)
Indiana (239)
Iowa (10)
Japan (526)
Kansas (93)
Kentucky (11)
Louisiana (18)
Maine (16)
Maryland (1012)
Massachusetts (7671)
Michigan (136)
Minnesota (353)
Mississippi (3)
Missouri (40)
Montana (17)
Nebraska (6)
Nevada (59)
New Hampshire (22)
New Jersey (2297)
New Mexico (13)
New York (2385)
North Carolina (1116)
North Dakota (7)
Northern California (4829)
Ohio (231)
Oklahoma (11)
Oregon (26)
Pennsylvania (1719)
Puerto Rico (12)
Rhode Island (27)
South America (282)
South Carolina (13)
Southern California (3830)
Tennessee (64)
Texas (1295)
United States (31696)
Utah (154)
Vermont (1)
Virginia (187)
Washington D.C. (38)
Washington State (766)
West Virginia (1)
Wisconsin (73)
Wyoming (1)
333,980 Results for "enlivex therapeutics ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
July 13, 2026
·
5 min read
Press Releases
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
January 26, 2026
·
5 min read
Press Releases
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
April 23, 2026
·
5 min read
Press Releases
Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
April 21, 2026
·
5 min read
Press Releases
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
March 25, 2026
·
5 min read
Press Releases
Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors
November 24, 2025
·
6 min read
Press Releases
Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement
November 27, 2025
·
5 min read
Press Releases
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
March 23, 2026
·
6 min read
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics Ltd. announced the closing of its previously announced registered direct offering to a single healthcare-focused institutional investor of an aggregate of 3,571,429 ordinary shares and clinical milestone-linked warrants.
May 29, 2024
·
5 min read
Deals
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Enlivex Therapeutics Ltd. today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale in a registered direct offering of an aggregate of 3,571,429 ordinary shares.
May 28, 2024
·
6 min read
1 of 33,398
Next
